The Molluscum Contagiosum market report also offers comprehensive insights into the Molluscum Contagiosum market size, share, Molluscum Contagiosum epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Molluscum Contagiosum market size growth forward.
Some of the key highlights from the Molluscum Contagiosum Market Insights Report:
-
Several key pharmaceutical companies, including Verrica Pharmaceuticals, Novan and Ligand Pharmaceuticals, Veloce Biopharma, and others, are developing novel products to improve the Molluscum Contagiosum treatment outlook.
-
In December 2024, Verrica Pharmaceuticals Inc., a company focused on dermatology therapeutics for skin conditions requiring medical treatments, announced that its development and commercialization partner, Torii Pharmaceutical Co. Ltd., had submitted a New Drug Application (NDA) for TO-208 (also known as VP-102 and marketed as YCANTH® in the U.S.) for the treatment of Molluscum Contagiosum in Japan.
-
The global prevalence of Molluscum Contagiosum is rising, leading to increased demand for effective treatments. This demand is driven by factors such as population growth, greater awareness, and changes in lifestyle, creating opportunities for market expansion.
-
In 2023, the Molluscum Contagiosum Treatment Market in the US was valued at approximately USD 1.2 billion.
-
Among the EU4 and the UK, France had the largest market size for molluscum contagiosum treatment, reaching around USD 168 million, followed by Germany at USD 156 million, and the UK at USD 154 million. These figures are expected to change over the forecast period (2024-2034) as ongoing research and development efforts potentially lead to the discovery of more effective therapies for treating the condition.
-
The Molluscum Contagiosum treatment market shows strong potential, fueled by the growing prevalence of the condition, heightened awareness, more treatment options, and a competitive market environment. However, challenges like regulatory barriers and the ongoing need for innovation remain key concerns for industry stakeholders.
-
Current treatments for Molluscum Contagiosum include physical removal techniques like cryotherapy and curettage, as well as topical medications such as imiquimod and cantharidin solution, which focus on clearing lesions and alleviating symptoms.
-
FDA-approved therapies for Molluscum Contagiosum include YCANTH (VP-102/cantharidin), a topical solution for patients aged 2 and older, and ZELSUVMI (berdazimer), a gel offering a unique delivery system for targeted topical dosing.
-
Unmet needs in this area arise from the lack of consensus on clinical guidelines, highlighting the need for more standardized treatment approaches and novel therapies. Addressing these gaps requires research into innovative solutions and the development of evidence-based guidelines to improve patient outcomes.
-
While Molluscum Contagiosum is a self-limiting condition that often resolves on its own within 6-12 months, reducing the urgency for treatment, this can also slow market growth. Despite a limited treatment pipeline, Veloce Biopharma’s VBP-245, a broad-spectrum antimicrobial topical gel, shows promise for the treatment of Molluscum Contagiosum.
-
As per DelveInsight analysis, the Molluscum Contagiosum market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Molluscum Contagiosum Market Landscape
Molluscum Contagiosum Overview
Molluscum contagiosum, commonly known as water warts, is a widespread skin infection caused by the poxvirus. It presents as small, round, raised bumps or lesions on the skin, typically with a central indentation or core. Although these lesions are usually painless, they can become itchy, inflamed, or irritated, especially if scratched or rubbed. The infection is caused by the molluscum contagiosum virus, which is part of the poxvirus family.
The virus spreads through direct skin-to-skin contact with an infected individual or by touching contaminated objects like towels, clothing, or toys. The main symptom is the appearance of small, flesh-colored or pearly bumps on the skin, usually measuring 2 to 5 millimeters in diameter. These bumps can occur individually or in clusters and can appear anywhere on the body, though they are most commonly found in warm and moist areas such as the armpits, groin, abdomen, and buttocks. Molluscum contagiosum is highly contagious and can spread through close personal contact, sharing contaminated objects, or contact with contaminated surfaces in public places like swimming pools or gyms.
Individuals with weakened immune systems, such as those with HIV/AIDS or undergoing chemotherapy, are at a higher risk of developing severe or widespread molluscum contagiosum infections. Children, particularly those in daycare or with frequent skin-to-skin contact, are also more vulnerable.
Do you know the treatment paradigms for different countries? Download our Molluscum Contagiosum Market Sample Report
Molluscum Contagiosum Epidemiology Insights
-
In 2023, France had the highest number of prevalent Molluscum Contagiosum cases among the EU4 and the UK, with an estimated 1.3 million cases, followed by Germany with about 1.2 million cases.
-
In the US, there were approximately 3 million cases of Molluscum Contagiosum in males and 4 million in females in 2023. The higher prevalence in females is attributed to factors such as differences in behavior, social interactions, and anatomical characteristics. For example, females may have more frequent skin-to-skin contact or engage in activities that increase the risk of transmission. Hormonal factors and immune response differences between genders may also contribute to the higher susceptibility in females.
Molluscum Contagiosum Epidemiology Segmentation
DelveInsight’s Molluscum Contagiosum market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Molluscum Contagiosum historical patient pools and forecasted Molluscum Contagiosum patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Molluscum Contagiosum Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:
-
Molluscum Contagiosum Prevalence
-
Age-Specific Molluscum Contagiosum Prevalence
-
Gender-Specific Molluscum Contagiosum Prevalence
-
Diagnosed and Treatable Cases of Molluscum Contagiosum
Visit for more @ Molluscum Contagiosum Epidemiological Insights
Molluscum Contagiosum Market Outlook
Molluscum Contagiosum treatment focuses on relieving symptoms, speeding up lesion healing, and minimizing transmission risks. Topical treatments are often used to reduce lesion size, inflammation, and the duration of infection. Common options include podophyllotoxin solution or cream, imiquimod cream, and other medications designed to stimulate the immune system to help clear the virus.
Recently approved treatments like ZELSUVMI (berdazimer) combine berdazimer sodium with a hydrogel. YCANTH, a promising drug, uses cantharidin to create blisters on lesions, aiding in their removal. Some off-label oral antiviral medications like cimetidine and cidofovir have been used, though their effectiveness and potential side effects remain uncertain. As a result, the treatment landscape for molluscum contagiosum is evolving, driven by the need for more effective and convenient options.
While traditional methods like cryotherapy and curettage are still commonly used, there’s growing interest in topical treatments such as immunomodulators, antiviral agents, and nitric oxide-based therapies. Ongoing research into new treatments like photodynamic therapy and immune response modifiers offers hope for future alternatives. Despite the variety of treatments, there are still unmet needs in safety, efficacy, patient convenience, pediatric formulations, and the psychological effects of the condition.
The treatment pipeline for molluscum contagiosum is somewhat limited, but Veloce Biopharma’s VBP-245, which uses povidone-iodine, shows promise and could significantly impact the market during the 2024-2034 forecast period.
According to DelveInsight, the molluscum contagiosum market is expected to evolve during the forecast period, driven by the launch of new therapies, increasing awareness among healthcare providers and patients, and advancements in diagnostic technology, leading to a growing number of diagnosed cases.
Molluscum Contagiosum Marketed Drugs
-
YCANTH (VP-102/cantharidin): Verrica Pharmaceuticals
-
ZELSUVMI (berdazimer) topical gel: Novan and Ligand Pharmaceuticals
Molluscum Contagiosum Emerging Drugs
-
VBP-245 (povidone-iodine): Veloce Biopharma
Molluscum Contagiosum Key Companies
-
Verrica Pharmaceuticals, Novan and Ligand Pharmaceuticals, Veloce Biopharma, and others
For more information, visit Molluscum Contagiosum Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Molluscum Contagiosum Market Report:
-
11 Years Forecast
-
7MM Coverage
-
Descriptive overview of Molluscum Contagiosum, causes, signs and symptoms, diagnosis, treatment
-
Comprehensive insight into Molluscum Contagiosum epidemiology in the 7MM
-
Molluscum Contagiosum marketed and emerging therapies
-
Molluscum Contagiosum companies
-
Molluscum Contagiosum market drivers and barriers
Table of Contents:
1 Molluscum Contagiosum Market Key Comprehensive Insights
2 Molluscum Contagiosum Market Report Introduction
3 Competitive Intelligence Analysis for Molluscum Contagiosum
4 Molluscum Contagiosum Market Analysis Overview at a Glance
5 Executive Summary of Molluscum Contagiosum
6 Molluscum Contagiosum Epidemiology and Market Methodology
7 Molluscum Contagiosum Epidemiology and Patient Population
8 Molluscum Contagiosum Patient Journey
9 Molluscum Contagiosum Treatment Algorithm, Molluscum Contagiosum Current Treatment, and Medical Practices
10 Key Endpoints in Molluscum Contagiosum Clinical Trials
11 Molluscum Contagiosum Marketed Therapies
12 Molluscum Contagiosum Emerging Therapies
13 Molluscum Contagiosum: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Molluscum Contagiosum
16 Molluscum Contagiosum Market Key Opinion Leaders Reviews
18 Molluscum Contagiosum Market Drivers
19 Molluscum Contagiosum Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Molluscum Contagiosum Epidemiology 2034
DelveInsight’s “Molluscum Contagiosum – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Molluscum Contagiosum epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Molluscum Contagiosum Pipeline 2024
“Molluscum Contagiosum Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Molluscum Contagiosum market. A detailed picture of the Molluscum Contagiosum pipeline landscape is provided, which includes the disease overview and Molluscum Contagiosum treatment guidelines.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/